BUSINESS OVERVIEW INOVIQ Ltd (ASX:IIQ) is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. The product portfolio includes commercial exosome isolation products and an adjunct bladder cancer test, clinicalstage diagnostics for breast and ovarian cancers, and a preclinical-stage CAR-exosome therapeutic program for solid tumours. HIGHLIGHTS INOVIQ made significant progress during financial year 2025 and up to the date of this report. The Company grew its EXO-NET customer base and delivered key development milestones across its exosome diagnostic, exosome therapeutic and SubB2M diagnostic pipeline. Our exosome diagnostic for screening ovarian cancer delivered outstanding performance for early-stage detection, our CAR-NKexosome therapeutic achieved in vitro cytotoxic efficacy in breast cancer cells and our neuCA15-3 breast cancer monitoring test showed disease specificity. These results further validate INOVIQ’s technology platforms and substantially de-risk our diagnostic and therapeutic pipeline for breast and ovarian cancers. 4 INOVIQ Limited Commercial › EXO-NET® revenue and customers grew across Europe, US and Asia via global partner Promega Corporation › NEURO-NET™ brainderived exosome isolation tool validated in Parkinson’s Disease and made available for collaborations › Promega developing combination EXO-NET exosome isolation and Maxwell RNA extraction products to expand product offering and provide automated solutions Review of Operations We are pleased to present the Group’s Annual Report for the financial year ended 30 June 2025 and provide an update on further strategic and operational progress since year end.
RkJQdWJsaXNoZXIy MjE2NDg3